Christopher Cherry, MD
Cardiovascular Disease · Jackson, TNNPI 1609861293
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,681 of the $3,636 with a category attached, or 73.7%. 17 manufacturers reported payments, led by Angiodynamics, Inc. at 36.2% of the total.
Across 145 payments — averaging $25.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$1K
- Novartis$445
- Pfizer$311
- E.r. Squibb & Sons, L.L.C.$299
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$290
- Abbott$286
- plus $688 from 11 others
Across 36 payments — averaging $14,266 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$300K
- Boehringer Ingelheim$106K
- Pfizer$105K
- Boehringer Ingelheim Canada Ltd.ltee$731
- Boehringer Ingelheim France S.a.s.$723
- Boehringer Ingelheim Pharma GmbH & Co.kg$712
What the payments were for
- Travel & lodging$95526%
- Food & beverage$2,68174%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Angiodynamics, Inc. | 3 | $1,317 |
| Novartis | 52 | $445 |
| Pfizer | 25 | $311 |
| E.r. Squibb & Sons, L.L.C. | 14 | $299 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 24 | $290 |
| Abbott | 2 | $286 |
| Medtronic | 4 | $234 |
| Alnylam Pharmaceuticals Inc. | 5 | $111 |
| Abiomed | 1 | $98 |
| Novo Nordisk | 4 | $83 |
| Boehringer Ingelheim | 4 | $59 |
| Amgen | 2 | $26 |
| Boston Scientific | 1 | $18 |
| Bayer | 1 | $15 |
| AstraZeneca | 1 | $15 |
| Philips North America LLC | 1 | $15 |
| Lexicon Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MitraClip$152
- CARDIOMEMS$134
- Micra$108
- COBALT DR MRI SURESCAN$102
How this compares
$3,636 in reported general payments places this provider in the 60th percentile of 429 cardiovascular disease providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 569 | $439,204 |
| Repatha SureclickEvolocumab | 145 | $108,491 |
| EntrestoSacubitril/Valsartan | 98 | $83,185 |
| XareltoRivaroxaban | 38 | $35,628 |
| Praluent PenAlirocumab | 24 | $19,764 |
| BrilintaTicagrelor | 11 | $11,575 |
| FarxigaDapagliflozin Propanediol | 13 | $10,018 |
| JardianceEmpagliflozin | 13 | $8,785 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 17 | $5,189 |
| Ranolazine ErRanolazine | 52 | $5,038 |
| Metoprolol Succinate | 243 | $3,173 |
| ClopidogrelClopidogrel Bisulfate | 192 | $2,595 |
| Potassium Chloride | 91 | $2,456 |
| Rosuvastatin Calcium | 146 | $2,258 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 77 | $1,861 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $311 | $439,204569 claims |
| NovartisEntresto | $445 | $83,18598 claims |
| AstraZenecaBrilinta, Farxiga | $15 | $21,59324 claims |
| Boehringer IngelheimJardiance | $59 | $8,78513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 429 cardiovascular disease providers in Tennessee.
Other cardiovascular disease in Jackson
- Adeyinka AgbetoyinJackson$112K
- Elliot KurbanJackson$68K
- Shahzad ShahJackson$15K
- Mohsin AlhaddadJackson$14K
- Alexander AlperovichJackson$13K
- Nirav PatelJackson$12K
- David MetzgerKingsport$555K
- Christopher EllisNashville$527K
- Joann LindenfeldNashville$270K
- Steven GubinMemphis$248K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.